Cited by 145Sarcoma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersLymphoma Diagnosis and Treatment

The DOI matches its Crossref record; 15 of the 17 references it cites were found in a registry or an index.

Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial

Open access

Pollack, Seth M., Redman, Mary W., Baker, Kelsey K., Wagner, Michael J., Schroeder, Brett A., Loggers, Elizabeth T., Trieselmann, Kathryn, Copeland, Vanessa C., Zhang, Shihong, Black, Graeme, McDonnell, Sabrina, Gregory, Jeffrey, Johnson, Rylee, Moore, Roxanne, Jones, Robin L., Cranmer, Lee D.·2020·JAMA Oncology

DOI 10.1001/jamaoncol.2020.3689PMC PMC7489365

Open this paper in CoChat — free account Open PDF

Abstract

IMPORTANCE: Anthracycline-based therapy is standard first-line treatment for most patients with advanced and metastatic sarcomas. Although multiple trials have attempted to show improved outcomes in patients with soft-tissue sarcoma over doxorubicin monotherapy, each has fallen short of demonstrating improved outcomes. OBJECTIVE: To evaluate the safety and efficacy of doxorubicin in combination with pembrolizumab in patients with advanced, anthracycline-naive sarcomas. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized clinical trial used a 2-stage phase 2 design and was performed at a single, academic sarcoma specialty center. Patients were adults with good performance status and end-organ function. Patients with all sarcoma subtypes were allowed to enroll with the exception of osteosarcoma, Ewing sarcoma, and alveolar and embryonal rhabdomyosarcoma. INTERVENTIONS: Two dose levels of doxorubicin (45 and 75 mg/m2) were tested for safety in combination with pembrolizumab. MAIN OUTCOMES AND MEASURES: Objective response rate (ORR) was the primary end point. Overall survival (OS) and progression-free survival (PFS) were secondary end points. Correlative studies included immunohistochemistry, gene expression, and serum cytokines. RESULTS: A total of 37 patients (22 men; 15 women) were treated in the combined phase 1/2 trial. The median (range) patient age was 58.4 (25-80) years. The most common histologic subtype was leiomyosarcoma (11 patients). Doxorubicin plus pembrolizumab was well tolerated without significant unexpected toxic effects. The ORR was 13% for phase 2 patients and 19% overall. Median PFS was 8.1 (95% CI, 7.6-10.8) months. Median OS was 27.6 (95% CI, 18.7-not reached) months at the time of this analysis. Two of 3 patients with undifferentiated pleomorphic sarcoma and 2 of 4 patients with dedifferentiated liposarcoma had durable partial responses. Tumor-infiltrating lymphocytes were present in 21% of evaluable tumors and associated with inferior PFS (log-rank P = .03). No dose-limiting toxic effects were observed. CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, doxorubicin plus pembrolizumab was well tolerated. Although the primary end point for ORR was not reached, the PFS and OS observed compared favorably with prior published studies. Further studies are warranted, especially those focusing on undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02888665.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2020.3689

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Judson, I. R., Verweij, J., Gelderblom, H. A. J., Hartmann, J. T., Schöffski, P., Blay, J., Kerst, J. M., Šufliarský, J., Whelan, J. S., Hohenberger, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70063-4 · Cited by 1,185
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
Tap, W. D., Jones, R. L., Tine, B. A. V., Chmielowski, B., ELIAS, A. D., Adkins, D., Agulnik, M., Cooney, M. M., Livingston, M. B., Pennock, G. K., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30587-6 · Cited by 584
Self-citation
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Seddon, B. M., Strauss, S. J., Whelan, J. S., Leahy, M. G., Woll, P. J., Cowie, F. J., Rothermundt, C. A., Wood, Z., Benson, C., Ali, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30622-8 · Cited by 529
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas
Toulmonde, M., Penel, N., Adam, J., Chevreau, C., Blay, J., Cesne, A. L., Bompas, E., Piperno-Neumann, S., Cousin, S., Grellety, T., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1617 · Cited by 420
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
Wilky, B. A., Trucco, M. M., Subhawong, T. K., Florou, V., Park, W., Kwon, D., Wieder, E., Kolonias, D. S., Rosenberg, A. E., Kerr, D. A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30153-6 · Cited by 404
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas
Tap, W. D., Wagner, A. J., Schöffski, P., Martín‐Broto, J., Krarup‐Hansen, A., Ganjoo, K. N., Yen, C., Razak, A. R. A., Spira, A. I., Kawai, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.1707 · Cited by 310
Self-citation
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
D’Angelo, S. P., Shoushtari, A. N., Agaram, N. P., Kuk, D., Qin, L., Carvajal, R. D., Dickson, M. A., Gounder, M. M., Keohan, M. L., Schwartz, G. K., et al. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.11.001 · Cited by 305
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
Tap, W. D., Pápai, Z., Tine, B. A. V., Attia, S., Ganjoo, K. N., Jones, R. L., Schuetze, S. M., Reed, D. R., Chawla, S. P., Riedel, R. F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30381-9 · Cited by 304
Self-citation

Flagged first, then by citations

Show all 17 references

2 of the 17 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–145 of 145

Prioritization of novel agents for further investigation in pediatric non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children’s Oncology Group
Crane, J. N., Douglass, D. P., Oberoi, S., Collins, N. B., Gupta, A. K., Metts, J. L., Avutu, V., Cruz, F. S. D., Davis, J. L., Federman, N. C., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115600 · Cited by 2
High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience
Nasr, L. F., Zoghbi, M., Lazcano, R., Nakazawa, M. S., Bishop, A. J., Farooqi, A. S., Mitra, D., Guadagnolo, B. A., Benjamin, R. S., PATEL, S. R., et al. (2024) · Cancers · doi:10.3390/cancers16091763 · Cited by 3
A Rare Entity of the Anterior Chest Cage Rib Chondrosarcoma: A Case Report and Review of Literature
Al-Mourgi, M., & Shams, A. M. (2024) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2024.09.005 · Cited by 2
Diagnostic trap: a case report of intimal sarcoma occurring in the left atrium
Ye, H., Jing, Y., Luo, S., & Wang, J. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1509505 · Cited by 2
Combination of immune checkpoint inhibitors and anthracyclines as a potential first-line regimen for dedifferentiated liposarcoma: systematic review and meta-analysis
Zhuang, A., Xiao, Z., Chengfei, X., Zhe, X., Chen, Y., Chenhe, Z., Xie, F., Fan, Y., Mengmeng, X., Ye, F., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04007-1 · Cited by 3
Favorable response to nivolumab combined with radiotherapy for retroperitoneal leiomyosarcoma
Ishihara, S., Shiraishi, K., Yoshida, A., Mori, T., Ueno, T., Ono, H., Ichikawa, H., Yagishita, S., Kohsaka, S., Goto, Y., et al. (2025) · International Cancer Conference Journal · doi:10.1007/s13691-025-00771-0 · Cited by 2
Hyperprogressive Disease in Leiomyosarcoma: A Threat to the Use of Single-Agent Anti-Pd-(L)1 Therapy?
Assi, T., & Mir, O. (2022) · Immunotherapy · doi:10.2217/imt-2021-0297 · Cited by 2
Combination Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma
Baa, A. K., & Rastogi, S. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7868 · Cited by 2
Immune checkpoint inhibition in sarcomas: time to be histology-specific?
Napolitano, A., Huang, P. H., Jones, R. L., & Tu, C. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00500-9 · Cited by 1
Self-citation
Progress in understanding of relationship of chronic hypoxia and hypoxia-inducing factors with liver cancer
Chi, Z.-C. (2025) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v33.i1.11 · Cited by 1
Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review
Li, J., Zhou, X., Wu, L., Ma, J., Tan, Y., Wu, S., Zhu, J., Wang, Q., & Shi, Q. (2025) · BMC Cancer · doi:10.1186/s12885-025-13712-0 · Cited by 1
Pembrolizumab and Sarcoma: A meta-analysis
Ali, R. M., Omar, S. S., Abdalla, S. H., Fattah, F. H., Hamalaw, S. R., Hamasalih, H. M., Mustafa, A. M., Karim, S. O., Mahmood, Y. M., Abdulkarim, M. M., et al. (2025) · Judi Clinical Journal · doi:10.70955/jcj.2025.6 · Cited by 1
A Case Report of Promising Response to Combination Therapy With an Immune Checkpoint Inhibitor (Pembrolizumab) and Multi‐Targeted Tyrosine Kinase Inhibitor (Pazopanib) in Metastatic De‐Differentiated Chondrosarcoma
Youssef, M., & Grimison, P. (2026) · Cancer Reports · doi:10.1002/cnr2.70426 · Cited by 1
A new kinetic-mechanistic approach to elucidate optical bioanalysis of doxorubicin in alkaline solution
Behyar, M. B., Hasanzadeh, M., Shadjou, N., & Alimirzalu, F. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103329 · Cited by 1
Utidelone in patients with advanced soft tissue sarcoma refractory to anthracycline and antiangiogenic therapy (UTISARC): a single-arm phase II study
Liu, J., Fu, Y., (30851), B. W., Tang, Y.-F., Deng, Y., & Jiang, Y. (2026) · BMC Medicine · doi:10.1186/s12916-026-04990-x · Cited by 1
A Phase 1/2 study of ontorpacept (TTI-621) in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma
Movva, S., Allgood, V., Chugh, R. K., Davis, L. E., Bailey, H. H., Milhem, M. M., Monga, V., Attia, S., Mangla, A., Bruns, I., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03574-z · Cited by 1
Evidence for the Current Management of Soft-tissue Sarcoma and Gastrointestinal Stromal Tumors and Emerging Directions
Dossa, F., & Gladdy, R. A. (2022) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2022.07.010 · Cited by 1
Radiation Followed by IO Is the Way to Go
Haddox, C. L., & Baldini, E. H. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.01.229 · Cited by 1
Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition
Waldschmidt, J. M., Haug, L., Riedhammer, C., Deinzer, C. K. W., Zimmermann, M., Heidemeier, A., Raab, P., Rudert, M., Hendricks, A., Lock, J. F., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1518775 · Cited by 1
Immunotherapy in sarcoma
Koseła-Paterczyk, H. (2020) · Nowotwory Journal of Oncology · doi:10.5603/njo.2020.0057 · Cited by 1
The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group ( TOG ) study
Güven, D. C., Aykan, M. B., Muğlu, H., Bayram, E., Helvacı, K., Dursun, B., Celayir, M., Celebiyev, E., Nayır, E., Erman, M., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6869
Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsPreprint
Paluncic, J., Carrero, Z. I., Fischer, L. K., Schulz, J. P., Hanf, D., Jády, A., GutierrezTenorio, F., Klimova, A., Dagostino, C., Wolf, I., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.18.705724 · Cited by 1
Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency
Alcindor, T., Papke, D. J., Venkataraman, V., Wagner, M. J., Merriam, P., Haddox, C. L., Wagner, A. J., Solimini, N. L., Jambhekar, A., & George, S. (2026) · JCO Precision Oncology · doi:10.1200/po-26-00414
Self-citation
Combination Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma—Reply
Wagner, M. J., Cranmer, L. D., & Pollack, S. M. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7873
Self-citation
Clinical characteristics and treatment outcomes of women with recurrent uterine leiomyosarcomaPreprint
Yao, H., Li, N., & Yuan, H. (2022) · doi:10.22541/au.166996370.05187114/v1
Additional file 4 of Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer
Yu, Y., Sun, Y., Li, Z., Li, J., & Tian, D. (2023) · Figshare · doi:10.6084/m9.figshare.22612393
Additional file 5 of Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer
Yu, Y., Sun, Y., Li, Z., Li, J., & Tian, D. (2023) · Figshare · doi:10.6084/m9.figshare.22612396
Additional file 6 of Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer
Yu, Y., Sun, Y., Li, Z., Li, J., & Tian, D. (2023) · Figshare · doi:10.6084/m9.figshare.22612399
Current status and future perspectives of immunotherapy for abdominal liposarcoma: From basic research to clinical practice
Zhuang, A., Xi, Z., Cheng, Y., Zhang, C.-H., & Li, W. (2025) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v33.i2.81
Microsatellite instability and PD-L1 expression in sarcomas: current evidence and clinical perspectives
Ibe, O. E., Ulasov, I. V., Ивановна, С. С., & Reshetov, I. V. (2025) · Medical Oncology · doi:10.1007/s12032-025-03039-y
Maintenance after first-line treatment for advanced soft tissue sarcoma
Penel, N., Pautier, P., & Blay, J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104959
Activation of the STING pathway potentiates the antitumor efficacy of doxorubicin in soft-tissue sarcoma
Choi, W., Lee, G. Y., & Kong, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1634503
Additional file 2 of Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer
Yu, Y., Sun, Y., Li, Z., Li, J., & Tian, D. (2023) · Figshare · doi:10.6084/m9.figshare.22612387
Additional file 1 of Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer
Yu, Y., Sun, Y., Li, Z., Li, J., & Tian, D. (2023) · Figshare · doi:10.6084/m9.figshare.22612384
Additional file 3 of Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer
Yu, Y., Sun, Y., Li, Z., Li, J., & Tian, D. (2023) · Figshare · doi:10.6084/m9.figshare.22612390
Phase IB/II Trial with Correlative Analyses of Doxorubicin plus Durvalumab Combination in Patients with Advanced Soft Tissue Sarcoma
Yun, K., Sim, N. S., Shin, S., Lee, Y. H., Baek, W., Han, Y. D., Park, J., Kim, S. K., Cho, I., Jung, I., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2633
CAR-T cell immunotherapy in rhabdomyosarcoma
Kozani, P. S., Shokoohi, S. D., & Kozani, P. S. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07773-3
Immune Checkpoint Inhibitors in Advanced Soft Tissue Sarcomas
Alkhawaldeh, K. M., Ribeiro, M. F., & Brohl, A. S. (2026) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2026.02.006
Immunotherapy for Leiomyosarcoma: Current Status and Perspectives
Qi, H., Zhang, H., Wang, Q., Wang, X., Min, L., Zhou, Y., Liu, B., & Li, R. (2026) · Journal of Immunology Research · doi:10.1155/jimr/6614578
The promise of immunotherapy in the treatment of sarcoma: A state-of-the-art review of practice changing research and future directions
Kulkarni, N. J., Kelly, C. M., & Bartlett, E. K. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2674185
Drug-eluting bead transarterial chemoembolization combined with immune checkpoint inhibitors is associated with improved progression-free survival in locally advanced or metastatic sarcoma: a retrospective propensity score-matched analysis
Zhou, C., Li, H., Qian, G., Yu, W., Zheng, S., Shen, Z., & Wang, Y. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261450424
Successful Sequential Multimodal Therapy for Lingual Rhabdomyosarcoma in a Young Adult: Case Report
Domínguez, J. V., Arizmendi, J. V., Saldaña-Herrera, V. G., Meneses‐Morales, I., Juárez, G. E. D., Vega, C. E. A., Chávez, R. L., & Bárcenas, A. O. (2026) · Case Reports in Oncological Medicine · doi:10.1155/crom/7742907
Programmed death-ligand 1 (PD-L1) expression in different sarcoma subtypes
Teoman, G., Karaman, E., Ayas, M. S., & Sayğın, İ. (2026) · Journal of Health Sciences and Medicine · doi:10.32322/jhsm.1902291
Immunotherapy-based salvage therapy in advanced soft tissue sarcoma after first-line chemotherapy: a retrospective single-center analysis with emphasis on undifferentiated pleomorphic sarcoma
Liao, Z., Huang, J., Liu, H., Zhang, C., Li, T., Wang, H., Liu, Y., Ren, S., Ren, Z., Wu, H., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1918276
Molecular landscape of chondrosarcoma: From tumor biology to therapeutic vulnerabilities
Belluzzi, E., Pozzuoli, A., Trovarelli, G., Angelini, A., & Ruggieri, P. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189736

Authors: Pollack, S. M., Redman, M. W., Baker, K. K., Wagner, M. J., Schroeder, B. A., Loggers, E. T., Trieselmann, K., Copeland, V. C., Zhang, S., Black, G., McDonnell, S., Gregory, J., Johnson, R., Moore, R., Jones, R. L., & Cranmer, L. D.
Affiliations: University of Washington (US)
Fred Hutch Cancer Center (US)
Virginia Mason Medical Center (US)
Institute of Cancer Research (GB)
Corresponding author: Pollack, Seth M.
ORCID: Pollack, Seth M.
Redman, Mary W.
Baker, Kelsey K.
Wagner, Michael J.
Schroeder, Brett A.
Loggers, Elizabeth T.
Copeland, Vanessa C.
Zhang, Shihong
Black, Graeme
Jones, Robin L.
Cranmer, Lee D.
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2020-11-01
Volume: 6
Issue: 11
Pages: 1778
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2020.3689
PMC: PMC7489365
OpenAlex: W3083776688
Cited by: 142
References: 17
Citations by year: 2026: 16 · 2025: 31 · 2024: 29 · 2023: 25 · 2022: 25 · 2021: 15 · 2020: 1
FWCI: 9.72
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
Locations: JAMA Oncology (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords: doxorubicin, pembrolizumab, soft tissue sarcoma, immune checkpoint inhibitors, combination chemotherapy, objective response rate, progression-free survival, overall survival, tumor-infiltrating lymphocytes, leiomyosarcoma, malignant fibrous histiocytoma, dedifferentiated liposarcoma, drug safety and tolerability
MeSH terms: Adult, Aged, Aged, 80 and over, Doxorubicin, Female, Humans, Male, Middle Aged, Sarcoma, Anthracyclines, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks